Enhancing Domestic Drug Manufacturing Competitiveness Act

Hozzl · 2025-03-17T14:05:01Z

Explore the details of House Bill 1405 Enhancing Domestic Drug Manufacturing Competitiveness Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/17/2025, 2:05 PM

Summary of Bill HR 1405

Bill 119 HR 1405, also known as the Pharmaceutical Manufacturing Modernization Act, aims to address the regulatory barriers that hinder the growth and establishment of new pharmaceutical manufacturing facilities in the United States. The bill directs the Comptroller General of the United States to conduct a comprehensive study to identify and assess these key regulatory obstacles.

The study will focus on understanding the specific regulations and policies that create challenges for pharmaceutical companies looking to expand or build new manufacturing facilities in the US. By identifying these barriers, lawmakers hope to develop targeted solutions that will streamline the regulatory process and encourage investment in domestic pharmaceutical manufacturing.

In addition to assessing regulatory barriers, the bill also aims to explore other factors that may impact the competitiveness of the US pharmaceutical manufacturing industry. This includes examining the availability of skilled labor, infrastructure needs, and potential incentives that could attract pharmaceutical companies to invest in domestic production. Overall, the Pharmaceutical Manufacturing Modernization Act seeks to promote the growth of the pharmaceutical manufacturing sector in the US by addressing regulatory challenges and identifying opportunities for improvement. By conducting a thorough study of these issues, lawmakers hope to develop policies that will support the expansion and siting of new pharmaceutical manufacturing facilities, ultimately benefiting both the industry and consumers.

Congressional Summary of HR 1405

Enhancing Domestic Drug Manufacturing Competitiveness Act

This bill requires the Government Accountability Office (GAO) to study and report to Congress on key regulatory barriers to pharmaceutical manufacturing in the United States.

Specifically, GAO must identify and assess, including by engaging stakeholders, barriers that impede expansion or siting of pharmaceutical manufacturing facilities in the United States or make the United States less competitive than other countries as a location for such facilities. GAO must consider (1) whether environmental or other regulations significantly delay and increase the cost of expanding or siting pharmaceutical manufacturing facilities in the United States; (2) the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency; and (3) specific actions for regulators to address the identified barriers.

Finally, the report must include recommendations for streamlining regulatory barriers and facilitating technological solutions to foster U.S. pharmaceutical manufacturing.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 1405

Bill HR 1405 is currently in the status of Bill Introduced since February 18, 2025. Bill HR 1405 was introduced during Congress 119 and was introduced to the House on February 18, 2025. Bill HR 1405's most recent activity was Referred to the House Committee on Energy and Commerce. as of February 18, 2025

Bipartisan Support of Bill HR 1405

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 1405

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 1405

To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.